EyePoint Pharmaceuticals, Inc. (EYPT) Dividend History

Company News

• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  EyePoint Pharmaceuticals, a biopharmaceutical company focused on retinal diseases, announced the grant of stock options to seven new employees as inducement awards. The options have an exercise price of $5.72 per share and vest over four years.

  GlobeNewswire Inc.
• EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

  EyePoint Pharmaceuticals, a biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, announced it will host a conference call to report its Q1 2025 financial results and provide updates on its pipeline, including the Phase 3 trials for its lead candidate DURAVYU in wet AMD and DME.

  GlobeNewswire Inc.
• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  EyePoint Pharmaceuticals, a biopharmaceutical company focused on developing treatments for serious retinal diseases, announced that it granted stock options to four new employees as inducement awards.

  GlobeNewswire Inc.
• EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

  EyePoint Pharmaceuticals, a biopharmaceutical company focused on developing treatments for serious retinal diseases, announced that its CEO will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Conference. The company's lead product candidate, DURAVYU, is in Phase 3 trials for wet age-related macular degeneration and recently completed a Phase 2 trial for diabetic macular edema.

  GlobeNewswire Inc.
• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  EyePoint Pharmaceuticals, a biopharmaceutical company focused on retinal diseases, announced the grant of stock options to two new employees as inducement awards. The options have an exercise price of $6.50 per share and vest over four years.

  GlobeNewswire Inc.